PBRM1 and nonpapillary renal cell carcinoma: While the role of PBRM1 status as a predicator of immunotherapy remains to be validated, PBRM1-mutant ccRCC seems to present a distinct nonimmunogenic phenotype from PBRM1-wild type ccRCC [12].